免疫组化在卵巢转移性癌与原发性癌鉴别诊断中的应用

目的对免疫组化在卵巢转移性癌与原发性癌鉴别诊断中的应用和效果进行研究。方法以我科2013年3月至2015年3月收治的25例胃肠道转移性癌（转移性癌组）与30例原发性癌患者（原发性癌组）为对象．通过免疫组化法对其进行CA125检测。结果检测结果显示，转移性癌组在CA125阳性率上为4％，原发性癌组在CA125阳性率上为83．3％，两组比较差异较大（P〈0．05）。结论免疫组化在卵巢转移性癌与原发性癌鉴别诊断中有重要意义．以CA125检测来说,当CA125显示为阳性时可以诊断为原发性癌．当CA125显示为阴性时可以诊断为胃来源的卵巢转移性癌。

Objective immunohistochemical in metastatic ovarian cancer and the application of the differential diagoosis of primary carcinoma and effect were studied. Methods I division in March of 2013-2015 on March 25 eases of metaslatic earcinoma of the gastro intestinal tract （metastatic cancer group） and 30 cases of primary carcinoma （primary carcinoma group） as the object, hy the immunohistochemical method of CA125, detection. Results the test results show that the metastatic carcinoma group on CA125. positive rate was 4%, the primary carcinoma group on CA125 positive rate was 83.3 %, two groups compare differences （P〈0. 05）. Conclusion immunohistochemical in metastatic ovarian cancer and primary carcinoma has important significance in the differential diagnosis of CA125 in detecting, when CA125 show positive can be diagnosed with primary carcinoma, when CA125 show negadve can he diagnosed as gastric origin of metastatic ovarian carcinoma.